The purpose of this task force was to critically analyze nine non-criteria manifestations of
APS to support their inclusion as APS classification criteria. The Task Force Members�…

New clinical, laboratory and experimental insights, since the 1999 publication of the
Sapporo preliminary classification criteria for antiphospholipid syndrome (APS), had been�…

The antiphospholipid (Hughes) syndrome (APS) is characterized by arterial and/or venous
thrombosis and pregnancy morbidity in the presence of anticardiolipin antibodies and/or�…

OBJECTIVE: To apply the new American College of Rheumatology nomenclature for
neuropsychiatric systemic lupus erythematosus (NPSLE), determine the prevalence of the�…

The antiphospholipid syndrome (APS) refers to persistent antiphospholipid antibodies (aPL)
associated with thrombotic and/or obstetrical complications. The endothelial cell is a target�…

Neurological involvement in antiphospholipid antibody syndrome (APS) is common, and its
occurrence increases morbidity and mortality. Patients may present variable neurological�…

Antiphospholipid antibodies (aPL) are associated with neurological diseases such as stroke,
migraine, epilepsy and dementia and are thus associated with both vascular and non�…

Objective: To examine the predictors of time-to-seizure occurrence and their impact on
damage accrual and mortality in LUMINA, a multiethnic (Hispanic, African American and�…

OBJECTIVE: To assess the frequency of epilepsy in primary and secondary
antiphospholipid syndrome (APS); to analyze the clinical and laboratory features�…

A multicenter study was set up to evaluate the prevalence, clinical and biological
significance of antiphosphatidylethanolamine antibodies (aPE) in thrombotic patients with or�…